Lancet study: Covaxin 50-pc effective against symptomatic COVID

According to the first real-world assessment of the COVID-19 vaccine published in the Lancet Infectious Diseases journal, two doses of COVID-19 vaccine Covaxin (BBV152) are 50 percent efficacious against symptomatic COVID-19 disease.

From April 15 to May 15, researchers analysed 2,714 hospital personnel at the All India Institute of Medical Sciences (AIIMS) in Delhi who were symptomatic and completed a COVID-19 RT-PCR test. "There were 2714 symptomatic tested patients left," the research said, "of whom 1,617 tested positive for SARS-CoV-2 and 1,097 tested negative."

"With an interval of at least 14 days between administration of the second dosage and day of testing, the unadjusted efficacy of two doses of BBV152 against symptomatic RT-PCR-confirmed SARS-CoV-2 was 53 percent. The effectiveness was assessed to be 50 percent after adjustments. Two doses given at least 28 days before testing had an adjusted effectiveness of 46 percent, and two doses given at least 42 days before testing had an adjusted effectiveness of 57 percent "It was stated.

Covaxin was certified for emergency use in India for adults aged 18 and up in January of this year. The vaccine was added to the World Health Organization's (WHO) list of approved COVID-19 vaccines for emergency use earlier this month.

Bharat Biotech says, Developing Covaxin was an enormous challenge

Lancet study reveals Covaxin is safe, effective against symptomatic COVID

Lancet also admitted Indian Covaxin, describes vaccine as 'highly effective'

 

- Sponsored Advert -

Most Popular

- Sponsored Advert -